

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6



Acme Pharmaceuticals

KDISCOVERER

700

User Name : 702

Password : 704

☒ Remember my user name and password


706

Login **New User**

If you forget your password, please call 1-800-PASSWORD.

Copyright (c) 1999 - Andersen Consulting LLP. All rights reserved.

FIG. 7



Acme Pharmaceuticals **KDISCOVERER - Welcome!** [Edit Profile](#) [Sitemap](#) [Logout](#)

[Recent News](#) [Organizer](#) [Research](#) [Development](#) [Commercialization](#) [Search & Browse](#)

[Target](#)

Cardiology/Vascular Diseases*

- Cardiology
 - Cholesterol
 - Chronic Occlusive Arterial...
- Acute Myocardial Infarction
- Angina Pectoris
- 5-AMP Deaminase*
- ACE (Angiotensin-converting Enzyme)*
- Angiotensin Receptor*
- Antiarrhythmics
 - Arteriolar
- Bronchodilator Agent
- Calcium Channel
- Coronary
- Digitalis Glycosides
- Epithelial Sodium Channel*
- Ganglionic Blocker
- Inotropic Drug
- Miscellaneous
 - Non-Radiopaque Agent
 - Peripheral
 - Radiopaque Agent
 - Selective C-Gmp. Phosphod...
- Sympatholytic
- Vasodilator
- Veinotonics/Vasculoprotec...
- Venosclectosing Agent
- Veratrum Alkaloids
- Xanthines

THE BERNIN®
For evaluation use only

Therapeutic Area : Cardiology/Vascular Diseases

Quick Search and Browse [Therapeutic Area](#) [card](#) [Search](#) [Help](#)

Copyright (c) 1999 - Andersen Consulting LLP.




FIG. 10

KDISCOVERER - Welcome!

Recent News | Organizer | Research | Development | Commercialization | Search | Browse

Acme Pharmaceuticals | Edit Profile | Sitemap | Logout

Compound

Captopril

Capoten*
 Capozide 25/15*
 Capozide 25/25*
 Capozide 50/15*
 Capozide 50/25*
 Patent 5238924*
 ACE (Angiotensin-converti...
 Achard JM
 Ahikali R
 Akalin S
 Akifaji H
 Congestive Heart Failure*
 Angiotensin II receptor anta...
 Angiotensin II-induced renal...
 Angiotensin II regulates the s...
 Dosing of ACE inhibitors in...
 Efficacy and safety of spira...
 A randomized, double-blind...
 Beneficial effects of MET-...
 EXP3174: the ACE antagonist...
 Hemodynamic and neurohu...
 ACE inhibitors improve en...
 Captopril increased mitoc...
 Effect of ED management...
 Hemodynamic responses...
 Angioedema due to losartan...
 Captopril treatment impro...
 Effect of adreno-cortico...
 Angiotensin II concentratio...
 Captopril-induced toxic epi...
 Effect of captopril on the co...
 Inhibitor analysis of angiot...

THE MAIN
 For evaluation use only

Compound Name : Captopril
 Patent (s) : 5238924
 Drug(s) : Captopril, Capoten, Capozide 25/15, Capozide 25/25, Capozide 50/15, Capozide 50/25, Hy

FIG. 11




FIG. 12




FIG. 13

1402

1404

1406

1114

Acme Pharmaceuticals **KDISCOVERER - Welcome!** **Logout**

Recent News **Organizer** **Research** **Development** **Commercialization** **Search & Browse**

Patent

Patent 4660291
 Patent 5164402
 Patent 5532246
 Patent 5763454
 Patent 5942519

«Bristol Myers Squibb»
 «Merck»
 «FDA 18343»
 «Smith Ronald D.»

Patent 5238924
 «Captgril»
 Visit Source

THE MAIN
 For evaluation use only

Patent Number : 5238924
 Exp. Date : AUG 24, 2010
 Assignee : Merck

1116

1004

Quick Search and Browse **Therapeutic Area** **card** **Search** **Help**


1400

FIG. 14

1500

United States Patent: 5,238,924 - Microsoft Internet Explorer

File Edit View Favorites Tools Help



US PATENT & TRADEMARK OFFICE

PATENT FULL TEXT AND IMAGE DATABASE

Help Home Boolean Manual Number Order Copy PTDLS

Hit List Bottom Shopping Cart Order Copy

Images

United States Patent
Smith

5,238,924
August 24, 1993

Treatment of renal diseases with ace inhibitors

Abstract

There is disclosed the use of angiotensin converting enzyme (ACE) inhibitors to alter the progression of renal diseases by affecting intraglomerular hemodynamics and proteinuria, i.e., affecting blood pressure within the functioning, filtering tissue of the kidney and the quantity of albumin in the urine.

Patent 4680
Patent 5162
Patent 5502
Patent 5769
Patent 5942

FILED

For evaluation use only

Patent Number : 5
Exp. Date : 20
Assignee : M



Quick Search and Browse

Copyright (c) 1999 - Anderson

1502

FIG. 15

1600



Monitored Items

- Organizations:
 - Merck
- Targets:
 - TR27 K-channel
- Scientists:
 - Abiskali R

Organizations

Merck

- FDA: 20560
- FDA: 20685
- Patent 4370829
- Alfuzosin is not associated with dermatomyositis.

Targets

TR27 K-channel

- Patent 4188390

Scientists

Abiskali R

- The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model.



1618

FIG. 16

1620

1700




FIG. 17




FIG. 18A




FIG. 18B




FIG. 18C





FIG. 18D

FIG. 19

1900






FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIGURE 26